Long-Term Investors Should Consider Buying the Dips in Intec Pharma Ltd [NTEC] Stock

Intec Pharma Ltd [NTEC] shares are down more than -69.44% this year and recently increased 0.14% or $0.5 to settle at $3.61. NTEC has a short ratio of 0.69. This implies that the market is currently less bullish on the outlook for NTEC.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 5, November 2020, Intec Pharma Reports Third Quarter 2020 Financial Results and Provides Corporate Update. According to news published on Yahoo Finance, Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces financial results for the third quarter ended September 30, 2020 and provides a corporate update.

Analyst Birdseye View:

The most recent analyst activity for Intec Pharma Ltd [NASDAQ:NTEC] stock was on March 26, 2018, when it was Reiterated with a Buy rating from Maxim Group, which also raised its 12-month price target on the stock from $8 to $12. Before that, on October 11, 2019, ROTH Capital Recapitulated a Neutral rating and elevated its amount target to $1. On February 28, 2018, Ladenburg Thalmann Initiated a Buy rating. On February 26, 2018, H.C. Wainwright Initiated a Buy rating. On September 21, 2017, Oppenheimer Reiterated an Outperform rating and increased its price target to $15. On September 16, 2015, Maxim Group Initiated a Buy rating and boosted its amount on this stock to $9. On September 11, 2015, ROTH Capital Initiated a Buy rating and boosted its target amount on this stock to $9.50.

In the past 52 weeks of trading, this stock has oscillated between a low of $2.20 and a peak of $15.82. Right now, the middling Wall Street analyst 12-month amount mark is $10.00. At the most recent market close, shares of Intec Pharma Ltd [NASDAQ:NTEC] were valued at $3.61.


The Principal structure of this organization shows its whole liability to whole principal at 10.43 and the whole liability to whole assets at 6.31. It shows enduring liability to the whole principal at 6.20 and enduring liability to assets at 0.04 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 3.06 points at 1st support level, the second support level is making up to 3.00. But as of 1st resistance point, this stock is sitting at 3.22 and at 3.32 for 2nd resistance point.

Intec Pharma Ltd [NTEC] reported its earnings at -$0.95 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.87/share signifying the difference of -0.08 and -9.20% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$1 calling estimates for -$1.07/share with the difference of 0.07 depicting the surprise of 6.50%.

Important Ratio’s To Watch

Quick ratio, showing Cash ratio at 1.21. Now if looking for a valuation of this stock’s amount to book ratio is 1.56.

Insider Stories

The most recent insider trade was by Dexcel Pharma Technologies Ltd, 10% Owner, and it was the sale of 0.11 million shares on Feb 04. Dexcel Pharma Technologies Ltd, the 10% Owner, completed a sale of 80000.0 shares on Feb 03. On Jan 31, Dexcel Pharma Technologies Ltd, 10% Owner, completed a sale of 0.73 million shares.